Cancer Anorexia-Cachexia Syndrome (CACS) Global Market Report 2025

The cancer anorexia-cachexia (CACS) syndrome market size has grown rapidly in recent years. It will grow from $3.51 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth during the historic period was driven by the increasing prevalence of cancer, heightened awareness among healthcare professionals, a stronger emphasis on enhancing the quality of life for cancer patients, the expansion of clinical trials, and the rise in pharmaceutical collaborations and partnerships.

The cancer anorexia-cachexia (CACS) market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The projected growth during the forecast period can be attributed to higher cancer survival rates, increased investments in oncology supportive care, the expansion of personalized medicine, a greater emphasis on multimodal therapies, and the development of healthcare infrastructure. Key trends expected in this period include advancements in palliative care, the emergence of targeted therapies, innovations in drug delivery systems, the integration of AI in drug development, and the continued evolution of personalized medicine.

The increasing prevalence of cancer is expected to drive the growth of the cancer anorexia-cachexia syndrome market. Cancer encompasses a wide range of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The global rise in cancer cases is attributed to factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, heightened awareness, genetic predispositions, and infections associated with certain cancers. Cancer anorexia-cachexia syndrome (CACS) plays a crucial role in addressing this growing prevalence by managing severe weight loss and malnutrition in cancer patients, ultimately enhancing their quality of life and treatment outcomes. For example, in August 2024, a report published by Macmillan Cancer Support, a UK-based charitable organization, indicated that over 3 million people in the UK are living with cancer, with projections estimating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is fueling the expansion of the cancer anorexia-cachexia syndrome market.

The rise in healthcare expenditure is also anticipated to contribute to the growth of the cancer anorexia-cachexia syndrome market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, encompassing both public and private sector spending. The increase in healthcare expenditure is driven by factors such as an aging population, the growing incidence of chronic diseases, advancements in medical technology, and a heightened demand for quality healthcare services. Cancer anorexia-cachexia syndrome (CACS) significantly contributes to this rising expenditure by requiring specialized treatments, nutritional support, and palliative care for patients, thereby increasing the costs associated with managing cancer-related complications. For instance, in May 2024, data from the Office for National Statistics, a UK-based government department, revealed a 5.6% rise in total healthcare expenditure in nominal terms from 2022 to 2023, representing a substantial acceleration compared to the 0.9% growth recorded in 2022. This increasing healthcare expenditure is a key factor driving the expansion of the cancer anorexia-cachexia syndrome market.

Leading companies in the cancer anorexia-cachexia syndrome market are prioritizing the development of innovative solutions, such as monoclonal antibody therapies, to enhance treatment efficacy, improve patient outcomes, and address unmet clinical needs. Monoclonal antibody therapies involve laboratory-engineered antibodies designed to target specific antigens on cancer cells, aiding the immune system in recognizing and attacking them more effectively. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, reported positive results from a Phase II clinical trial of ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The promising findings from this study offer new hope for patients suffering from this debilitating condition, which currently has limited effective treatments. The Phase II trial results indicate significant progress in addressing the inflammatory processes that contribute to muscle loss and weight decline in cancer patients. This novel treatment approach aims not only to improve physical function but also to enhance the overall quality of life for cancer patients, representing a crucial advancement in oncology care.

Major players in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer anorexia-cachexia (CACS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer anorexia-cachexia syndrome (CACS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer anorexia-cachexia syndrome (CACS) is a multifaceted and complex condition commonly seen in cancer patients, marked by significant metabolic disturbances. It arises from a combination of inflammatory responses, hormonal fluctuations, and impaired nutrient utilization, often leading to poor prognosis and resistance to treatment.

The key aspects of CACS management include preventing weight loss, addressing appetite suppression, reducing muscle wasting, and controlling inflammation. Strategies for weight loss prevention aim to sustain body weight and muscle mass by enhancing nutritional intake and counteracting cancer-related metabolic disruptions. Various therapeutic approaches, including corticosteroids and combination treatments, are employed to manage CACS. These treatments function through different mechanisms, such as appetite stimulation, anti-inflammatory effects, hormonal modulation, and cannabinoid-based interventions. They are administered via multiple routes, including oral, intravenous, subcutaneous, and transdermal delivery, and are utilized in various healthcare settings, such as hospitals, clinics, and home care environments.

The cancer anorexia-cachexia syndrome (CACS) market research report is one of a series of new reports that provides cancer anorexia-cachexia syndrome (CACS) market statistics, including the cancer anorexia-cachexia syndrome (CACS) industry global market size, regional shares, competitors with the cancer anorexia-cachexia syndrome (CACS) market share, detailed cancer anorexia-cachexia syndrome (CACS) market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer anorexia-cachexia syndrome (CACS) industry. This cancer anorexia-cachexia syndrome (CACS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer anorexia-cachexia syndrome (CACS) market consists of revenues earned by entities by providing services such as nutritional support, pharmacological treatments, palliative care, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.